Accurately of the order of 80% -90% detects the lung cancer In patients with suspected clinical or radiological findings, the analysis of the exhaled air with the electronic “nose”, as a new study notes.
The original ENOSE model (Spironose) detected lung cancer with a total accuracy of 92% in patients with chronic obstructive pulmonary disease (COPD) and 80% for a wider population of external patients. In a validation study, a newer model of the device gave a total accuracy of 83%.
The accuracy of lung cancer detection remained stable regardless of the characteristics of the tumor, of the disease stadium, a diagnostic center and other clinical agents, according to Alessandra Buma, the Medical Center of Radboud University in Nijmegen, the Netherlands, and the other authors of the study published in the Annals of Oncology.
The authors concluded that the present study faced key challenges that prevented the adoption of the ENOSE -supported intelligence in clinical practice, such as inadequate descriptions of analytical methods, the effect [VOCs] And the possible interference from other cancers in the control group and in patients with lung cancer, the small size of the sample and the absence of multicenter and perspective external validation studies.
As a result, the study provided ‘the information required to take the last steps towards applying this valuable diagnostic biomarker“, They added.
Future research should focus on evaluating the efficiency of ENOSE analysis at a diagnostic level for lung cancer in the context of screening and in determining its clinical utility in the oncology of oncology, both in comparison and in conjunction with the clinical Lung cancer, the researchers noted.
In the current stage, ENOSE technology ‘may be considered complementary to CT scan“, Said Gaetano Rocco of Memorial Sloan Kettering (MSK) Cancer Center in New York, which has developed a system based on the natural characteristics of volatile organic substances, as opposed to the Dutch system that has been trained to recognize specific volatile organic substances.
According to him, to begin to be used as a basic diagnosis tool, The device should first be tested in a significant number of patients with different prevalence of the disease and to already cured patients to confirm that ENOSE responds to the changes occurring in the tumor compared to the initial evaluation.
It is worth noting that the analysis of volatile organic compounds in the exhaled air during the breathing process has been investigated for years as a non -invasive, non -radiological method for the diagnosis of lung cancer.
The ENOSE Dutch platform uses an array of cross sensors, each of which is sensitive to a particular volatile organic union from a group of overlapping volatile organic compounds. Stemming from the oral cavity, respiratory tract and circulatory, volatile organic compounds reflect the metabolic process and normal (or pathophysiological) changes.
In a previous study, Spironose has managed to discern what healthy controls were in the control group, asthma patients, COPD patients and patients with lung cancer. More recently, Dutch researchers have shown that The ENOSE system detected lung cancer in COPD patients up to 2 years before clinical diagnosis with a sensitivity of 86% and a specialty of 89%.
In the framework of the clinical trial study of the results, from March 2019 to November 2023, researchers in two Dutch centers hired participants for an external ratification study. Using radiological and pathologic evaluations, researchers grouped patients in five categories: lung cancer without another concomitant cancer, lung cancer with another cancer, absence of cancer or no cancer or cancer).
Each participant underwent a double analysis of the exhalation, at the same time as blood tests and spirometry when possible. To confirm the discreet accuracy of ENOSE, exhaled air samples were also analyzed with mass spectrometry.
Data analysis included 364 patients in a training group and 121 in a validation group. In the educational team, ENOSE detected lung cancer at 216 (59%) of 364 patients, including 98 of 116 (84%) COPD patients. The results are translated into ROC-AUC 0.92 for the COPD subgroup and 0.80 for the entire group. With a predetermined sensitivity of 95%, ENOSE had a specialty of 72% for COPD patients and 51% for all patients, positive prognostic value (PPV) 95% and 74% and negative predictive value (NPV) 72% and 88%.
In the validation group, Enose detected lung cancer in 72 of 121 (60%) participants, resulting in ROC-AUC 0.83, 94%sensitivity, 63%specialty, PPV 79%and NPV 89%.
Last year, Rocco and his colleagues reported the findings of a study that evaluated the accuracy of Sloan Kettering’s Enose platform in 100 patients with clinical lung stage I. ENOSE analyzes had 86% agreement with histopathology. Analyzes led to 86 true positive results, two false negatives and 12 false positive results, resulting in F1 scores (correctness of forecasts) 92.5%.
Source: iatropedia.gr